[1] |
Wu Y, Wang Y, Wang L, et al. Burden of melanoma in China, 1990 -2017: findings from the 2017 global burden of disease study[J]. Int J Cancer, 2020,147(3):692⁃701. doi: 10.1002/ijc.32764.
|
[2] |
Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories[J]. Immunity, 2020,52(1):55⁃81. doi: 10.1016/j.immuni.2019.12.018.
|
[3] |
Sautès⁃Fridman C, Petitprez F, Calderaro J, et al. Tertiary lymphoid structures in the era of cancer immunotherapy[J]. Nat Rev Cancer, 2019,19(6):307⁃325. doi: 10.1038/s41568⁃019⁃0144⁃6.
|
[4] |
Engelhard VH, Rodriguez AB, Mauldin IS, et al. Immune cell infiltration and tertiary lymphoid structures as determinants of antitumor immunity[J]. J Immunol, 2018,200(2):432⁃442. doi: 10.4049/jimmunol.1701269.
|
[5] |
Jones GW, Jones SA. Ectopic lymphoid follicles: inducible centres for generating antigen⁃specific immune responses within tissues[J]. Immunology, 2016,147(2):141⁃151. doi: 10.1111/imm.12554.
|
[6] |
Seow D, Yeong J, Lim JX, et al. Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple⁃negative breast cancers[J]. Breast Cancer Res Treat, 2020,180(2):369⁃377. doi: 10.1007/s10549⁃020⁃05548⁃y.
|
[7] |
Marin ND, Dunlap MD, Kaushal D, et al. Friend or foe: the protective and pathological roles of inducible bronchus⁃associated lymphoid tissue in pulmonary diseases[J]. J Immunol, 2019,202(9):2519⁃2526. doi: 10.4049/jimmunol.1801135.
|
[8] |
Cabrita R, Lauss M, Sanna A, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma[J]. Nature, 2020,577(7791):561⁃565. doi: 10.1038/s41586⁃019⁃1914⁃8.
|
[9] |
Calderaro J, Petitprez F, Becht E, et al. Intra⁃tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma[J]. J Hepatol, 2019,70(1):58⁃65. doi: 10.1016/j.jhep.2018.09.003.
|
[10] |
Lee M, Heo SH, Song IH, et al. Presence of tertiary lymphoid structures determines the level of tumor⁃infiltrating lymphocytes in primary breast cancer and metastasis[J]. Mod Pathol, 2019,32(1):70⁃80. doi: 10.1038/s41379⁃018⁃0113⁃8.
|
[11] |
Goc J, Fridman WH, Sautès⁃Fridman C, et al. Characteristics of tertiary lymphoid structures in primary cancers[J]. Oncoimmunology, 2013,2(12):e26836. doi: 10.4161/onci.26836.
|
[12] |
Honda T, Egawa G, Kabashima K. Antigen presentation and adaptive immune responses in skin[J]. Int Immunol, 2019,31(7):423⁃429. doi: 10.1093/intimm/dxz005.
|
[13] |
Egawa G, Kabashima K. Role of lymphoid structure in skin immunity[J]. Curr Top Microbiol Immunol, 2020,426:65⁃82. doi: 10.1007/82_2020_206.
|
[14] |
Ladányi A, Kiss J, Somlai B, et al. Density of DC⁃LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor[J]. Cancer Immunol Immunother, 2007,56(9):1459⁃1469. doi: 10.1007/s00262⁃007⁃0286⁃3.
|
[15] |
Messina JL, Fenstermacher DA, Eschrich S, et al. 12⁃Chemokine gene signature identifies lymph node⁃like structures in melanoma: potential for patient selection for immunotherapy?[J]. Sci Rep, 2012,2:765. doi: 10.1038/srep00765.
|
[16] |
Cipponi A, Mercier M, Seremet T, et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases[J]. Cancer Res, 2012,72(16):3997⁃4007. doi: 10.1158/0008⁃5472.CAN⁃12⁃1377.
|
[17] |
Stowman AM, Hickman AW, Mauldin IS, et al. Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures[J]. Melanoma Res, 2018,28(3):237⁃245. doi: 10.1097/CMR.0000000000000439.
|
[18] |
Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma[J]. Nat Med, 2018,24(11):1655⁃1661. doi: 10.1038/s41591⁃018⁃0198⁃0.
|
[19] |
Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response[J]. Nature, 2020,577(7791):549⁃555. doi: 10.1038/s41586⁃019⁃1922⁃8.
|
[20] |
McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade[J]. Science, 2016,351(6280):1463⁃1469. doi: 10.1126/science.aaf1490.
|
[21] |
Eroglu Z, Zaretsky JM, Hu⁃Lieskovan S, et al. High response rate to PD⁃1 blockade in desmoplastic melanomas[J]. Nature, 2018,553(7688):347⁃350. doi: 10.1038/nature25187.
|